Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.80 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732277 | 0.90 | FGFR1 (0.64) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16655833 | 0.89 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659498 | 0.83 | FGFR1 (0.83) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659413 | 0.81 | FGFR4 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659502 | 0.81 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16656043 | 0.77 | FGFR1 (0.79) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659503 | 0.76 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16654577 | 0.75 | FGFR1 (0.75) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659444 | 0.74 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19732263 | 0.74 | FGFR1 (0.70) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.